Zacks Investment Research
10 Jun 2026, 22:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
What the story claims
4 claims · each scored for market impact
Recursion Pharmaceuticals (RXRX) is forecasted to report quarterly revenue of $11.99 million, a 37.64% decrease from the prior year. — A significant double-digit decline in quarterly revenue typically signals weakening business fundamentals or shrinking market share.
-0.40The consensus EPS estimate for Recursion Pharmaceuticals' upcoming quarter is -$0.25, representing a 39.02% improvement over the previous year. — Reducing losses is a positive trend for a biotechnology company in its growth phase.
+0.30The Zacks Consensus EPS estimate for RXRX has shifted upward by 1.99% over the past month. — Incremental upward revisions by analysts generally correlate with positive short-term price momentum.
+0.20Continue reading
6 related stories
Recursion Pharmaceuticals currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating suggests neutral sentiment and lacks a strong catalyst for immediate price movement.
+0.00Which stocks this story touches
The stock price fell 5.12% in the most recent session and quarterly revenue is projected to be down 37.64% year-over-year.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Zacks Investment Research
2h ago
